NIP
VTGN icon

Nicholas Investment Partners’s VistaGen Therapeutics VTGN Stock Holding History

Nicholas Investment Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-148,528
Closed -$3.92M – 202
2022
Q2 		$3.92M Sell
148,528
-3,818
-3% -$135K 0.37% 96
2022
Q1 		$5.67M Buy
152,346
+9,410
+7% +$410K 0.4% 90
2021
Q4 		$8.36M Buy
142,936
+50,058
+54% +$3.26M 0.53% 72
2021
Q3 		$7.63M Buy
92,878
+1,082
+1% +$94K 0.56% 70
2021
Q2 		$8.68M Buy
91,796
+19,763
+27% +$1.46M 0.54% 68
2021
Q1 		$4.6M Buy
+72,033
New +$4.81M 0.32% 98

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nicholas Investment Partners's VTGN Position: Q3 2022 in Review

Nicholas Investment Partners sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 148,528 shares — an estimated $3.92M sold.

Nicholas Investment Partners first reported a position in VTGN in Q1 2021 and held it in 6 quarters. The position peaked at $8.68M in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • Nicholas Investment Partners reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 148,528 VistaGen Therapeutics shares in Q3 2022, an estimated $3.92M.
  • Nicholas Investment Partners first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 6 quarters.
  • Nicholas Investment Partners's VistaGen Therapeutics position peaked at $8.68M in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on Nicholas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.